| Literature DB >> 35355906 |
Reza Rajesh1, Rajesh Joseph2, Philip Finny3.
Abstract
Entities:
Year: 2022 PMID: 35355906 PMCID: PMC8959205 DOI: 10.4103/ijem.ijem_339_21
Source DB: PubMed Journal: Indian J Endocrinol Metab ISSN: 2230-9500
Laboratory parameters of the patient[5]
| Parameters | Before discontinuation of Neomercazole and thyroidectomy | After thyroidectomy and discontinuation of Neomercazole | |||||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| 8/4/2021 | 14/4/2021 | 22/4/2021 | 05/5/2021 | 21/5/2021 | 3/6/2021 | 7/06/2021 | |
| Creatinine | 1.96 | 2.13 | 1.58 | 1.64 | 1.76 | 1.60 | |
| Urea | 36.4 | 51.3 | 54.2 | ||||
| FBS | 104 | ||||||
| HbA1C | 5.5 | ||||||
| GRBS | 132 | ||||||
| Urine Albumin | 2+ | 1+ | |||||
| dsDNA | Borderline + | ||||||
| Histones | +++ | ||||||
| TSH | 0.79 | ||||||
| Free T4 | 1.16 | ||||||
| Anti-TPO antibody | 0.51 | ||||||
| Anti-TSH receptor antibody | <0.8 | ||||||
Naranjo nomogram[5]
| Score | Interpretation |
|---|---|
| Total score ≥9 | Definite |
| Total score 5-8 | Probable |
| Total score 1-4 | Possible |
| Total score ≤0 | Doubtful |
Naranjo nomogram as applied to this patient
| 1. Are there previous conclusive reports on this reaction? (1/0/0) | 1 (Carbimazole has a documented association with nephritis) |
| 2. Did the adverse event occur after the suspected drug was administered? (2/1/0) | 2 (Serum creatinine increased 1.75 times above the baseline in the absence of other contributing nephrotoxins) |
| 3. Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered? (1/0/0) | 1 (Serum creatinine returned to baseline within 2 weeks of Carbimazole discontinuation) |
| 4. Did the adverse reaction reappear when the drug was re-administered? (2/1/0) | 0 (Carbimazole was not re-administered) |
| 5. Are there alternative causes (other than the drug) that could have caused the reaction? (1/2/0) | 2 (The patient’s presentation is not consistent with pre-or postrenal AKI, and no other medication changes were made after Carbimazole initiation) |
| 6. Did the reaction reappear when a placebo was given? (1/1/0) | 0 (Placebo was not administered) |
| 7. Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? (1/0/0) | 0 (Carbimazole concentrations are not routinely monitored; thyroid function tests did not demonstrate hypothyroidism) |
| 8. Was the reaction more severe when the dose was increased or less severe when the dose was decreased? (1/0/0) | 0 (Carbimazole dose was not adjusted; Carbimazole was discontinued) |
| 9. Did the patient have a similar reaction to the same or similar drugs in any previous exposure? (1/0/0) | 0 (The patient had not previously taken Carbimazole and had not ever been on propylthiouracil) |
| 10. Was the adverse event confirmed by any objective evidence? (1/0/0) | 1 (Laboratory monitoring demonstrated increased serum creatinine, and anti-histone antibodies, which are a feature of drug-induced toxicity, were also positive) |
| Total points | 7 (Probable adverse reaction) |